The repertoire of B cells secreting antibodies with unique antigen-binding specificities is produced at two stages: a primary B-cell repertoire is formed in the bone marrow through immunoglobulin gene rearrangements, whereas a secondary B-cell repertoire is generated in the peripheral lymphoid organs (spleen, lymph nodes and mucosa-associated lymphoid tissue) through somatic hypermutation and class-switch recombination upon antigen encounter. The latter events take place within highly specialized histological structures, designated B follicles, which are composed of distinct microanatomical compartments namely the follicle centre, lymphocytic corona and marginal zone. Each compartment comprises a particular subset of B cells, characterized by unique properties, thereby reflecting the complexity and variability in the spectrum of defence mechanisms against invading pathogens. The past years have spawned an avalanche of new data and information that encompasses both the structure and function of each compartment and its B cells. This review incorporates up-todate information on peripheral B-cell differentiation into a challenging working model, thereby pointing to the structural and functional imprint of both the T-cell-dependent and T-cellindependent immune response on the B follicle. As such, this article aims to form an excellent base for a better understanding of the normal counterpart of B-cell-derived haematological malignancies (leukemias and lymphomas).
Introduction
B cells represent one of the most important effectors in the immune surveillance against pathogens invading the human body. They generate the antibody-mediated immune response by the expression and subsequent secretion of an immunoglobulin (Ig) molecule, which is composed of two distinct chains, a heavy and a light chain, encoded at separate alleles. The variable regions of the heavy and light chains together form a domain that recognizes the antigen, and the heavy-chain constant (C) region determines how the antigen will be removed from the body. To express Ig, B cells go through distinct maturation stages and are subjected to selection procedures before becoming either memory B cells or plasma cells.
The lymphoid precursors are generated in the primary or central lymphoid organs. In human adults, a primary B-cell repertoire, derived from pluripotent haematopoietic stem cells, is produced in the bone marrow through Ig gene rearrangements. The B cells leaving the bone marrow are not yet exposed to external antigens and are called 'naïve' or 'virgin' B cells. These naïve B cells circulate through the bloodstream and are delivered to secondary or peripheral lymphoid organs. The latter are the major sites of antigen-induced differentiation of B cells and include the lymph nodes, spleen and mucosa-associated lymphoid tissue (MALT). The functional and structural subunit shared by all secondary lymphoid organs, wherein the affinitymaturation of B cells and the generation of memory B cells and plasma cells occur, is designated the 'composite nodule'. This microanatomic structure comprises a B follicle with adjacent T-cell area.
B follicles are composed of a complex network of follicular dendritic cells (FDC), B cells, a particular T-cell subset and tangible body macrophages. In non-stimulated lymphoid tissue, B follicles are composed of small lymphocytes and an underlying FDC network, and indicated as primary B follicles. Secondary B follicles develop upon antigen encounter and are composed of a germinal centre (GC) or follicle centre, and a surrounding lymphocytic corona. In those secondary lymphoid organs where an abundant influx of antigens is known to occur (spleen and MALT), a distinct zone surrounding the lymphocytic corona and designated the marginal zone (MZ) can be clearly recognized. This MZ is usually absent in lymph nodes, with the exception of those in the mesenterium. The lymphocytic corona and the MZ form the mantle of the B follicle. The adjacent T-cell area is composed of numerous T cells, a variable number of interdigitating reticulum cells and high endothelial venules.
Generation of the primary or central B-cell repertoire
In adults, the primary B-cell repertoire emerges from haematopoietic stem cells located in the bone marrow. B cell commitment of pluripotent stem cells is determined by transcriptional events involving the transcription factors PU.1, Ikaros, E2A (E-box factor 2A), EBF (early B-cell factor, also known as OLF1), PAX5 (paired box protein 5, also known as BSAP) and FOXP1 (Forkhead-box protein P1). 1, 2 It also implies a highly regulated series of genetic events, called Ig gene rearrangement, resulting in the membranous expression of a functional B-cell receptor (BCR). The variable regions of the Ig heavy chain are assembled from 123 variable (V), 27 diversity (D) and 6 junctional (J) genes present on the Ig heavy-chain gene locus on chromosome 14; the variable regions of the Ig light chains (which can be of k or l type) are assembled from V and J elements located at either the Igk or Igl gene locus on chromosome 2 and 22, respectively. As there are many different V, D and J segments in the germline, each B cell will generate a unique antibody. Ig gene rearrangement is dependent upon the activation of the recombination activating genes RAG1 and RAG2 in the early stages of B-cell maturation in the bone marrow. 3 Mice and human experiments demonstrated that RAG1 and RAG2 can be re-activated in later stages of B-cell maturation, more precisely in the GC, where they can mediate secondary Ig gene rearrangement. 4 However, the possibility of extramedullary RAG1 and RAG2 reactivation is not supported by all groups. 5 The earliest B cells in the bone marrow are the progenitor B cells or pro-B cells, which differ from haematopoietic stem cells by the expression of B-cell antigens (e.g. CD19 and CD79a) and by their ability to rearrange Ig genes ( Figure 1) . A pro-B-cell is transformed into an early pre-B cell once the D and J gene segments are recombined in the Ig heavy-chain gene locus (with the genes for light chains still remaining in germline configuration). Further rearrangements attach one of the V gene segments to the D-J segment and give rise to the late pre-B cell, which expresses a rearranged VDJ-Cm heavy chain on the cell surface. Subsequent rearrangement of the Ig light-chain gene locus leads to the surface expression of a complete IgM molecule and to a new B-cell stage, designated the immature B cell. The latter subsequently gives rises to the mature B cell that expresses both IgM and IgD at the cell surface as a result of alternative transcriptional termination and splicing of Ig heavy-chain mRNA rather than by DNA recombination. In contrast to immature B cells, mature B cells may leave the bone marrow and have the capacity of responding to the binding of an antigen by proliferating and differentiating into either plasma cells or memory B cells.
Generation of the secondary or peripheral B-cell repertoire
Mature, naïve B cells represent 60-70% of all circulating B cells and migrate into the spleen, lymph nodes and MALT where they form primary B-cell follicles. Upon antigen encounter, they further differentiate towards plasma cells and memory B cells through the so-called GC reaction, which comprises clonal expansion, somatic hypermutation (SHM) and class-switch recombination (CSR). Over the past decade, it became obvious that two particular subsets of peripheral B cells, namely MZ B cells and B1 cells, may short-circuit the GC reaction by rapidly proliferating and differentiating towards plasma cells outside the microenvironment of the GC; but whereas MZ B cells require antigen encounter to do so, B1 cells may differentiate in an antigen-independent manner. As such, although there are various classification systems in use, 6 the most appropriate way to classify peripheral B cells is to distinguish the following subsets: antigen-insensitive B1 cells and antigen-sensitive B2 cells, the latter consisting of GC B cells and MZ B cells. The mechanisms that determine whether a B cell will become a B1 cell, a GC B cell or a MZ B cell are discussed below.
Antigen-dependent differentiation of peripheral B cells: B2 cells
Upon encounter with the antigen for which they are prone, naïve B cells upregulate expression of CC-chemokine-receptor 7 (CCR7) and are attracted by a gradient of CC-chemokine ligands CCL19 and CCL21 towards the T-cell zone that borders the B follicles in the secondary lymphoid organs; 7 CCL19 and CCL21 are produced by the stromal cells in the T-cell zone and recognize CCR7 as their receptor. Only a small number of antigens are exclusively T-cell-independent as they directly activate naïve B cells by binding to their BCR. Most antigens however are T-cell-dependent as they require T cell help: 8 Antigen-activated B cells at the border of the B and T cell zone, either with or without the interaction of antigenpresenting cells and helper T cells, transform into large B-blasts that may follow two different pathways ( Figure 2 ): (1) most will proliferate in loco and differentiate into short-living plasma cells, which are responsible for the rapid release of low-affinity antibodies and thus first-line defence against the pathogen; (2) a few B-blasts will migrate into the primary B-cell follicle, where they proliferate, differentiate into GC B cells and generate longliving plasma cells (that produce high-affinity antibodies) and memory B cells. The first pathway (referred to as the non-GC or extrafollicular pathway) predominantly involves plasmacellular differentiation of MZ B cells and develops upon encounter with both T-cell-independent and T-cell-dependent antigens. 9 Conversely, the second pathway (designated the GC or follicular pathway) affects mainly recirculating naïve B cells and is linked to T-cell dependent antigens. 10 Within the GC pathway, the antigen-triggered, proliferating B cells form the GC while the non-antigen-triggered, naïve B cells are pushed aside and, thus, form the follicle mantle. This follicle, containing a GC and a mantle, is known as a secondary follicle.
The factors that induce B cells to differentiate in one direction or the other are not clear yet. Some authors believe that the type of B cell involved is the determining factor. Indeed, there is evidence to suggest that MZ B cells are preferentially recruited into the non-GC pathway, while recirculating B cells are the central players in GC reactions. 9, 10 This hypothesis is supported by mice experiments, which showed that B-cell commitment to either the GC or non-GC pathway is a cell-fate decision, regulated by signalling through Notch2, E-box factors (E2A), nuclear factor kB (NF-kB) and the BCR. Strong BCR signalling, absence of Notch2 signalling, deficient NF-kB signalling and high levels of E2A favour the GC pathway, whereas weak BCR signalling, presence of Notch2 signalling, activation of the NFkB and absence of E2A promote the non-GC pathway. 11 Conversely, it was shown that recirculating B cells have a dual potential since popliteal lymph nodes (which lack MZ B cells) from young pathogen-free mice generated both a GC and non-GC reaction following exposure to T-cell-dependent antigens; 12 moreover, it was also shown that MZ B cells can be recruited into the GC pathway and give rise, albeit with a delay, to the formation of GCs. 13 Therefore, other authors believe that the antigen is the main factor determining which differentiation pathway B cells will follow. Unfortunately, classification of pathogens into T-cell-dependent and T-cell-independent antigens cannot be easily done.
14 Bacteria, viruses and parasites contain a large number of distinct antigens. The fact that responses to most of these organisms are shaped by the presence of T cells does not preclude the possibility that T-cellindependent B cell activation might occur as part of most, if not all, humoral immune responses. 15 Nevertheless, despite these discrepancies in literature, there is a general consensus that MZ B cells dominate the T-cell-independent immune responses and early stages of T-cell-dependent immune responses (non-GC pathway), while GC B cells are the main players in the later stages of the T-cell-dependent immune responses (GC pathway).
The GC or follicular pathway. From the edge of the T-cell zone, a few antigen-specific B cells, in the company of antigenprimed T cells, will be recruited (back) into the B follicle to generate a GC reaction. This cellular migration following antigen encounter is determined by the B-and T-cell upregulation of CXC-chemokine-receptor 5 (CXCR5), which is the receptor for CXC-chemokine-ligand 13 (CXCL13), a chemokine that is produced by FDCs and stromal cells adjacent to the FDCs. 16, 17 The main purpose of recruiting antigen-specific B cells and T cells towards the GC is to generate a highly effective humoral immune response through iterative cycles of somatic antigen-receptor diversification and the selection of B cells with receptors' best fit for it. While the first is achieved by means of SHM and CSR, the latter is processed by survival signals delivered by both GC T cells and FDCs that interact with antigen-stimulated B cells. However, whereas the particular role of FDCs is to provide potent proliferative signals for positively selected B cell clones, the main role of the helper T cells is to eliminate autoreactive clones, to induce CSR and to promote differentiation towards either plasma cells or memory B cells. 18, 19 Within the GC microenvironment, proliferating B cells undergo a randomized introduction of mutations into the Ig gene region that encodes for the antigen-binding site, a process called SHM (mainly single nucleotide exchanges, but also deletions and duplications). 20 Since SHM occurs at random, most of these mutations do not increase, or even decrease, the affinity of the Ig-receptor or even completely prevent Igexpression by creating stop-codons or frame shifts. GC B cells with unfavourable mutations do not bind with high affinity to the antigen trapped by the FDCs and do not appropriately interact with the GC T cells. Therefore, they do not receive survival signals from these cells. In fact, more than 90% of the GC B cells die as a result of apoptosis, which is facilitated by the downregulation of the anti-apoptotic molecules BCL2 (B cell lymphoma 2) and BCL-X L (B cell lymphoma X L ). These cells are phagocytosed and digested by the so-called tangible-body macrophages. Only those GC B cells that synthesize highaffinity antibodies survive and will differentiate into long-living memory B cells or plasma cells.
Positively selected GC B cells activate T cells to express CD40-ligand (CD40L) and to secrete interleukin(IL)-4 and IL-10, which induces clonal B-cell expansion as well as CSR from IgM (and/or IgD) to IgG, IgA or less commonly IgE. 21 The latter results in a change in the effector function of the antibody, but leaves the V(D)J region unaltered. CSR consists of a recombination event that deletes the DNA between repeated sequences, called switch regions, which are located upstream of the C region of the Ig heavy-chain genes. 21 Although SHM and CSR display distinct molecular features, recently it became obvious that they are mediated by a shared pathway, which is controlled by a single B-cell-specific enzyme: activation-induced cytidine deaminase (AID). 22 Oncogenes like PAX5 and BCL6 may be mistargeted by AID, which can lead to aberrant hypermutation, translocation and subsequent tumourgenesis in B cells. (1) upon encounter with a T-cell-independent antigen, marginal zone B cells will proliferate in loco and differentiate into short-living plasma cells, which are responsible for the rapid release of low-affinity antibodies and thus first-line defence against the pathogen; (2) upon encounter with a T-cell-dependent antigen, B-blasts will migrate into the germinal centre, where they proliferate, undergo somatic hypermutations and isotype class switch, and differentiate into either long-living plasma cells (that produce high-affinity antibodies) and memory B cells. Abbreviations: TD (T-cell-dependent), TI (T-cell-independent), GC (germinal centre), MZ (marginal zone), CD40L (CD40 ligand), MHCII (major histocompatibilty antigens class II), BCR (B-cell receptor), TCR (T-cell receptor), FDC (follicular dendritic cell), MZDC (marginal zone dendritic cell). The non-GC or extrafollicular pathway. The non-GC reaction is mainly studied in the spleen, where a particular subset of naïve B cells housing in the MZ can be activated in a T-cell-independent manner by bacterial polysaccharides. Upon encounter with a T-cell-independent antigen, these B cells will rapidly proliferate, transform into plasmablasts and localize to the splenic bridging channels, which are located just outside the MZ and connect the periarteriolar lymphoid sheets (PALS) with the red pulp. 28 The topography of both MZ and bridging channels facilitates early encounter with blood-born antigens and rapid antibody release into the blood. As plasmablasts further differentiate into plasma cells, they will move deeper into the red pulp where they become associated with vessels or connective tissue fibres. Evidence indicates that plasmablasts are attracted towards the red pulp after upregulation of CXCR4, which binds its ligand CXCL12 that is expressed in the red pulp. 29 This coincides with downregulation of CXCR5 and CCR7 to escape the CXCL13-mediated attraction towards the GC, and the CCL19-and CCL21-mediated attraction towards the PALS. 29 The transition from plasmablast to plasma cell, which by definition involves coming out of the cell cycle, is determined by a peak in BLIMP1 and XBP1 expression, occurring 48 h after T-cell-independent stimulation. 9, 30 The mainly IgM-secreting plasma cells, generated by the non-GC pathway, will only survive for approximately 3 days before undergoing apoptosis. 31 In a similar manner, MZ B cells may also be recruited into the non-GC pathway following exposure to T-cell-dependent antigens, thereby implying that a non-GC reaction precedes the GC reaction. Although the non-GC immune response to a T-cell-dependent antigen lacks the high affinity of the GC response, it provides a rapid defence mechanism, in a matter of hours rather than days, to compensate for the delay in the GC reaction, which requires 5-7 days to develop. Therefore, the non-GC and GC reaction are often referred to as early and late immune response. As such, a two-phase model can be proposed to summarize the events following encounter with a T-celldependent antigen. 14 In the first phase, the antigen is recognized by a naïve B cell either in its free form, trapped in an immune complex with natural antibodies (see later) or bound on the surface of antigen-presenting cells. In response, and dependent upon the quantity of antigen as well as the signals provided by the antigen-presenting cells, antigen-specific B cells of the MZ will rapidly proliferate and transform into plasma cells outside the GC as described above. Secreted antibodies will enhance this T-cell-independent phase by binding antigen and complement that will provide co-stimulatory signals via complement receptors CR1 (CD35) and CR2 (CD21). Meanwhile, naïve antigen-specific T cells are also stimulated to proliferate until they are sufficiently expanded in number to make interactions with antigen-specific B cells possible and therefore induce the second phase of the immune response, being the T celldependent reaction within the GC. While the first, T-cellindependent phase guarantees the rapid release of low-affinity antibodies and ensures that the initially very rare antigenspecific T and B cells (estimated at less than 1 in 10 6 cells) meet, the second, T-cell-dependent phase induces SHM and CSR to generate a high-affinity immune response.
Dynamics of the B follicle
Interestingly, it was found that plasmablast-transformed MZ B cells in the non-GC pathway require CD11c-positive dendritic cells to survive in the PALs, bridging channels and red pulp, and to differentiate into plasma cells. 32 As such, it is believed that the interaction between these dendritic cells and B cells may, at least in part, represent the non-GC homologue of the CD40L-dependent interaction between helper T cells and B cells in the GC. Two members of the tumour necrosis factor (TNF) family, which are expressed by these CD11c-positive dendritic cells, were reported to play a key role in this intercellular interaction: BAFF (B-cell activating factor; also known as BLyS) and APRIL (a proliferation-inducing ligand).
9,30,33 BAFF binds to three receptors selectively expressed by B cells: TACI (transmembranous activator and calcium modulator and cyclophin-ligand interactor), BCMA (B-cell maturation antigen) and BAFFR (BAFF receptor); APRIL binds with high affinity to BCMA and with lower affinity to TACI but not to BAFF. 33, 34 Engagement of TACI, BCMA and BAFFR by BAFF and/or APRIL activates a CD40-like pathway that enhances B-cell survival (by upregulating NF-kB, which increases BCL2 expression) and that differentiates plasmablast into plasma cells (in the presence of IL15, which is produced by the CD11c-positive dendritic cells, and additional co-stimulation by BCR engagement). 35 The role of BAFF in the non-GC pathway is further emphasized by mice models as BAFF deficiency undermines both the T-celldependent and T-cell-independent immune response, while mice that lack its GC homologue CD40L are characterized by an impaired GC reaction and intact non-GC pathway. 36 In contrast to the class-switched, high-affinity antibodies of the GC reaction, it is generally believed that the major bulk of antibodies generated by the non-GC reaction consist of IgM antibodies with low antigen affinity. However, the possibility of SHM and CSR during the non-GC pathway is not fully understood yet. Although SHM is classically thought to be associated with the GC, it was shown that human MZ B cells may acquire low-level SHM in situ and therefore outside the GC. 37 This finding seems further supported by observations in patients with X-linked hyper-IgM syndrome (HIGM1), which results from mutations in the gene encoding the GC T-cell molecule CD40L. 38 As a consequence, cognate T-cell help fails and therefore B cells are unable to proliferate, form GCs and undergo CSR with subsequent immunodeficiency. Somewhat surprising, it was shown that the peripheral IgM þ IgD þ CD27 þ B-cell pool, which represents the only memory B-cell subset in HIGM1 patients, did carry hypermutations, although markedly reduced as compared with healthy age-matched controls. 39 As far as CSR is concerned, it is thought to be highly dependent on CD40/CD40L interactions that characterize the GC pathway. However, it is hypothesized that MZ B cells, recruited into the non-GC pathway, may receive to some extent CSR signals through CD40/CD40L interactions from T cells that pass through the MZ on their way to the GC. In conclusion, there are several lines of evidence that B cells involved in the non-GC pathway may class-switch and/or acquire some level of SHM, although less frequently as compared with GC B cells. 40 While IgM natural antibodies are present at high levels in the serum and limit the dissemination of blood-born pathogens, IgA natural antibodies are found mainly in the gut where they contribute to mucosal immunity. Natural antibodies are generally encoded by unmutated Ig genes. Owing to their polyspecific nature, they are decidedly skewed towards reactivity with both self-antigens and mainly bacterial, non-self-antigens. 40 Because of the unique feature of B1 cells to produce natural antibodies in an antigenindependent way, their ability to respond to antigenic stimulation, albeit in restricted fashion, is often overlooked. Bacterial polysaccharides and IL-4, for example, both stimulate strong proliferative responses of B1 cells, resulting in subsequent release of natural antibodies. 41 Also, B1 cells are superior to B2 cells in their ability to proliferate when stimulated with phorbol esters and IL-5. 42 Although the possibility of antigen-dependent activation of B1 cells is not well-defined yet, it is now believed that B1 cells, like MZ B cells, play an important role in vivo in the early T-cell-independent phase of the immune response.
Advances in phenotyping allowed murine B1 cell to be divided into two subsets, B1a and B1b cells. 40 B1a cells express surface CD5 and are derived from progenitors that are present in the fetal omentum and liver, but are absent from adult bone marrow; B1b-cells do not express surface CD5 (despite the presence of CD5 mRNA) and are derived from progenitors that are present in the fetal omentum and liver, and also in adult bone marrow. The transmembrane glycoprotein CD5, a surface marker otherwise restricted to T cells, functions as a negative regulator of BCR signalling by inhibiting nuclear translocation of NF-kB, which may promote inappropriate activation of autoreactive B1a cells. 43 Furthermore, not only do B1 cells differ from B2 cells by their production of natural antibodies, possible CD5 expression and peculiar progenitor cells, but also by their localization (B1 cells are mainly found in the peritoneal and pleural cavities and the lamina propria of the gut), their age-dependent development (B1-cell development is largely restricted to the fetal and neonatal period, while development of B2 cells begins late in the neonatal period and persist throughout life) and their self-renewing capacity (B1 cells are reconstituted by division of fully mature B1 cells). 40, 44 Recently, the existence of distinct developmental pathways for B1 and B2 cells was proven by the identification of adult bone marrow cells that give rise exclusively to B1 cells (Lin À CD45R lo-neg CD19 þ ). 45 Furthermore, the progenitors of B1 and B2 cells are distinguished by the expression of CD138 and MHC class II. 46 In analogy to mice, the human secondary B-cell repertoire also comprises a pool of B1 cells, which produces high amounts of natural antibodies that may bind to pathogens never encountered before and are likely to play an important defence mechanism in infancy. Although B1 cells are the major population in the human fetus and neonate (where they represent 80% of the B-cell pool), their percentage will decrease with age, coinciding with antigen exposure and thus, expansion of the B2-cell compartment. 47 In human adults, B1 cells only account for 15-20% of the circulating, splenic and tonsillar B lymphocytes, while B1b cells account for 2-6% of the circulating adult B cells (the occurrence of B1b cells in the secondary lymphoid organs is not clear). 48 Also, it has been reported that 19-76% of the B cells in the human peritoneal cavity are CD5-positive. 49 Whereas endogenously carrying CD5 B cells in the fetus and neonate are indisputable representatives of the human B1a-cell pool, it is still not clear whether adult B cells that are induced to express CD5 upon stimulation are a distinct differentiation stage of either B1a or B2 cells. It has been demonstrated that B cells with endogenous CD5 expression and B cells with induced CD5 expression respond differently to CD5 ligation -while crosslinking CD5 molecules enhances the expression of IL-2 and TNFa receptors on umbilical cord B1a cells, it will result in apoptosis by 48 h in human CD5-positive, tonsillar B cells. 50 As such, most authors classify adult B cells with induced CD5 expression as a peculiar subset of B2 cells. As in mice, there has been a longstanding debate over the lineage origins of human B1 cells -it is now believed 50 that in the fetus and neonate, the B1-cell repertoire is derived from stem cells mainly housing in liver, pleural and peritoneal cavities. After this early event, new stem cells migrate to the bone marrow, where the local environment will favour a switch in B-cell lymphopoiesis from a fetal B1-cell-type to an adult B2-cell-type. However, adult bone marrow still contains some residual, fetallineage-derived, self-renewing B1 cells (presumably B1b cells), precommitted to later expression of CD5. 51 Indeed, high numbers of CD5-positive B cells are recovered in the blood following bone marrow transplantation, suggesting that fetal ontogeny recapitulates after bone marrow transplantation, with the bone marrow being enriched for B1 cells. 52 Although B1 cells only account for a small percentage of B cells in human adults, their study gathers importance in view of their involvement in early lymphoid recovery following bone marrow transplantation, in malignancies (such as chronic lymphatic leukemia and mantle cell lymphoma), and in autoimmune diseases.
Micro-anatomical compartments of the B follicle
B cells of the secondary B-cell repertoire are found throughout the different compartments of the B follicle, namely the follicle centre (or GC) and the follicle mantle (Figure 3) . The latter comprises a lymphocytic corona and a MZ, which is particularly well developed in the splenic white pulp. Dynamics of the B follicle X Sagaert et al days 7-10 after initial antigen-priming, a secondary B follicle is polarized into a so-called 'dark zone' of rapidly dividing centroblasts and a 'light zone' of quiescent centrocytes. 8 Centroblasts are large, blastic-like cells with a round, vesicular nucleus, 1-3 prominent nucleoli and a narrow rim of basophilic cytoplasm. They lack surface Ig expression as they undergo SHM and CSR, and they switch off the genes that encode BCL2 and BCL2-related BCL-X L, which makes them susceptible to apoptosis if not positively selected. 10 Centroblasts express multiple antigens to interact with the FDCs present in the dark zone of GC where antigen-activated T cells are rather rare. 19 As such, centroblasts are marked by the adhesion molecules CD44L (CD44-ligand), LFA1 (lymphocyte functionassociated antigen 1) and VLA4 (very late-activated antigen 4) which recognize their respective FDC-ligands of CD44, ICAM1 (intercellular adhesion molecule 1) and VCAM1 (vascular adhesion molecule 1) to enhance cell-cell contact. 53 They also express receptors for the FDC molecules 86D, IL-15 and BAFF, but whereas the first two molecules provide potent proliferative signals, the latter is an anti-apoptotic molecule that rescues centroblasts from apoptosis. [54] [55] [56] After acquiring SHM and CSR, centroblasts exit the cell cycle to become centrocytes. These cells range in size from slightly larger than small lymphocytes to almost as large as centroblasts, and they are characterized by an irregular, sometimes deeply cleft nucleus, inconspicuous nucleolus and scant cytoplasm. They re-express surface Ig, with the same VDJ rearrangement as in the parent naïve B cell, but with an altered antibody-binding site (due to SHM) and an altered C-region (due to CSR). Using their newly expressed surface Ig, centrocytes bind the antigen and present it to the helper T-cells that are numerously present in the light zone of the GC. To ensure this cognate T-cell help, centrocytes express the molecules CD40, CD28, ICOS-L (inducible T cell co-stimulator ligand), CXCR5 and IL-12R (IL-12 receptor), which allows them to interact with their respective matching helper T-cell molecules CD40L, B7, ICOS, CXCL13 and IL-12. 18 The cognate interaction between centrocytes and helper T cells has several outcomes -it results in the survival and selection of high-affinity centrocytes, it provides signals for differentiation into long-living plasma cells and memory B cells, and it perpetuates GC reactions by stimulating centrocytes to recycle and become centroblasts again. 18 A unique feature of GC B cells, both centroblast and centrocytes, is the expression of BCL6 and CD10, which therefore represent two hallmarks of GC B cells and GC-derived malignancies. BCL6 is a nuclear zinc-finger transcription factor, required for GC formation and T-cell-dependent antibody responses in mice models. 57 It downregulates the expression of various genes, such as BLIMP1 58 (thereby allowing GC B cells to preserve their identity before differentiating into plasma cells) and the p53 tumour suppressor gene 59 (thereby preventing cellcycle arrest and thus facilitating the rapid expansion of GC B-cell population). Alterations of the BCL6 gene, including mutations and chromosomal translocation, represent a frequent genetic aberration associated with non-Hodgkin lymphoma, especially diffuse large B-cell lymphoma (DLBCL), a malignancy often derived from GC B cells. The membrane-associated CD10 molecule, also known as the common acute lymphocytic leukemia antigen (CALLA), is a neutral endopeptidase that first appears on pro-B cells, is lost during maturation to naïve B cells and reappears on the cell surface during GC maturation. 60 While BCL6 is essential for normal B-cell development and GC formation, CD10 seems to be redundant, as demonstrated in a perfectly healthy patient with congenital CD10 deficiency as well as in mice with targeted CD10 disruption. 61 
Lymphocytic corona
The inner part of the mantle zone of the B follicle is designated the lymphocytic corona. It is mainly composed of virgin B cells (with rearranged but unmutated Ig genes), which were pushed aside by the formation of the GC. Lymphocytic corona B cells strongly express both surface IgM and IgD as well as pan-B-cell antigens (CD19, CD20, CD79a). In contrast with precursor B cells in the bone marrow and GC B cells, they lack CD10 expression. Besides naïve B cells, the lymphocytic corona also comprises memory B cells, especially in lymphoid tissues where the MZ is poorly developed.
Marginal zone
The outer part of the mantle zone of the B follicle corresponds to the MZ, which is well developed in those secondary lymphoid organs where an abundant influx of antigens is known to occur. As such, it is especially well recognizable in the white pulp of the spleen. It is also easily observed in Peyer's patches and Waldeyer's ring. It is less obvious in lymph nodes except for the mesenteric ones. In mice, the splenic MZ is bordered outermost by the red pulp and innermost by the marginal sinus (the existence of a marginal sinus in humans is still debated). 62 As the central arteriole that carries blood to the spleen empties into the marginal sinus, many cells leaving or entering the white pulp can be found in transit in the MZ. In addition to being a transit area, the MZ is populated by a large number of resident cellsmacrophages, dendritic cells and MZ B cells. 62, 63 The latter demonstrated to be mostly memory B cells (marked by mutated Ig genes) with a minor component of naïve elements (marked by unmutated Ig genes) that are the main players in the non-GC pathway. 37 MZ B cells are slightly larger then lymphocytic corona B cells and are characterized by an abundantly clear cytoplasm and a pale, irregular, centrally located nucleus. Owing to their resemblance to centrocytes, MZ B cells have also been indicated as 'centrocyte-like' cells. MZ B cells express pan-Bcell markers (CD19, CD20, CD22), adhesion-molecules (LFA1, a 4 b 1 integrin), IgM, BCL2, CD1d (a MHC class Ib protein, linked to the presentation of lipid antigens) and CD9 (a scavengerreceptor family protein); they lack the expression of CD5, CD10, CD23 and BCL6. [62] [63] [64] Whereas the expression of IgD is generally considered to be lacking, in our and others' experience, IgD expression varies from negative to weakly positive. The negative/low expression of IgD by MZ B cells is useful to distinguish them from lymphocytic corona B cells, which are strongly IgD-positive. Other proteins reported to be strongly expressed by MZ B cells are alkine phosphatase and complement receptors CR1 (CD35), CR2 (CD21) and CR3 (CD18/11b). 6 Cells that resemble MZ B cells but with even more nuclear indentation and abundant cytoplasm, known as monocytoid B cells, are seen in clusters adjacent to subcapsular and cortical sinuses of some reactive lymph nodes, such as toxoplasma-induced lymphadenitis. 65 The immunophenotype of these monocytoid B cells is largely similar to that of MZ B cells with the exception of the expression of IgM and BCL2 which are variable and lacking in monocytoid B-cells, respectively. 65 MZ B cells and monocytoid B cells are, like follicular and lymphocytic corona B-cells, considered to be part of the large, antigen-driven B2-cell pool. However, the observation that MZ B cells have a similar V H gene rearrangement (with predominant rearrangement of V H 3 family genes) and a similar range of functional properties compared with B1 cells, makes some authors wonder whether MZ B cells do not represent the CD5-negative, CD5-mRNA-positive, naturally antibody-producing B1b-cell subset, a question that requires further investigation. 37 The MZ plays an essential role in response to T-cellindependent antigens, such as bacterial capsular polysaccharides, and because of its position next to the marginal sinus, it is also vital in detecting blood-borne pathogens and generating a firstline defence against them. 66 The involvement of the MZ in T-cellindependent immune responses is explained by the intrinsic capacity of MZ B-cells to mature rapidly in a matter of hours rather than days into plasma cells that secrete low-affinity antibodies. As such, a malfunction of the MZ has direct clinical impact. Until the age of 2 years, when the MZ is finally known to be fully developed, infants remain susceptible to infections with capsulated bacteria such as Hemophilus influenza, Streptococcus Pneumoniae and Neisseria meningitides. 67 Also, splenectomized individuals are notoriously susceptible to infections with these bacteria and therefore should be vaccinated. 68 
